Kala Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference
January 08 2020 - 8:00AM
Business Wire
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical
company focused on the development and commercialization of
therapeutics using its proprietary AMPPLIFY™ mucus-penetrating
particle (MPP) Drug Delivery Technology, today announced that it
will present at the 38th Annual J.P. Morgan Healthcare Conference
in San Francisco, CA. Mark Iwicki, Chairman, President and Chief
Executive Officer of Kala Pharmaceuticals, is scheduled to present
a corporate overview on Wednesday, January 15, 2020 at 11:30 a.m.
PT (2:30 p.m. ET).
To access a live webcast and subsequent archived recording of
the presentation, please visit the “Investors & Media” section
on the Kala website at http://kalarx.com.
About Kala Pharmaceuticals, Inc.
Kala is a biopharmaceutical company focused on the development
and commercialization of therapeutics using its proprietary
AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery
Technology, with an initial focus on the treatment of eye diseases.
Kala has applied the AMPPLIFY Drug Delivery Technology to a
corticosteroid, loteprednol etabonate (LE), designed for ocular
applications, resulting in the August 2018 FDA approval of
INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% for the
treatment of inflammation and pain following ocular surgery and its
lead product candidate, EYSUVISTM (loteprednol etabonate ophthalmic
suspension) 0.25%, for the temporary relief of the signs and
symptoms of dry eye disease.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200108005005/en/
Investors: Hannah Deresiewicz
hannah.deresiewicz@sternir.com 212-362-1200
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From May 2024 to Jun 2024
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From Jun 2023 to Jun 2024